Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2011 - 2026)

Abeona Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 42.29% year-over-year to -$17.1 million in Q1 2026; TTM through Mar 2026 was $66.8 million, a 251.43% increase from a year earlier, with the FY2025 full-year figure at $76.6 million, up 220.25% from the prior year.
• Net Income towards Common Stockholders advanced to -$17.1 million in Q1 2026 per ABEO's latest filing, from -$35.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $124.3 million in Q2 2025 and bottomed at -$35.3 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$11.8 million (2023), against an average of -$6.9 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 1580.34% in 2025; the steepest drop was 279.89% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$7.1 million in 2022, then slumped by 132.4% to -$16.6 million in 2023, then jumped by 43.98% to -$9.3 million in 2024, then tumbled by 279.89% to -$35.3 million in 2025, then surged by 51.67% to -$17.1 million in 2026.
• Per Business Quant, the three latest ABEO Net Income towards Common Stockholders figures stand at -$17.1 million (Q1 2026), -$35.3 million (Q4 2025), and -$5.2 million (Q3 2025).